Literature DB >> 27271032

The Evolution of Recommended Naloxone Dosing for Opioid Overdose by Medical Specialty.

Nicholas J Connors1, Lewis S Nelson2.   

Abstract

INTRODUCTION: Opioid abuse and opioid overdose deaths have increased significantly over the past decade. Naloxone is a potentially life-saving medication that can reverse opioid-induced respiratory depression, though precipitated opioid withdrawal can pose acute risks to the patient and medical personnel. The optimal naloxone dose is unclear and few studies address this question.
METHODS: A convenience sample of commonly available references were queried for the recommended IV naloxone dose. When dosing recommendations were different for opioid-tolerant patients these were also recorded.
RESULTS: Twenty-five references were located. 48% recommended a starting dose ≤ 0.05 mg while 36% recommend a dose ten-fold higher. More than half of medical toxicology and general medical sources recommended a low-dose strategy with a starting dose lower than 0.05 mg IV.
CONCLUSION: There are variations in the recommended doses for naloxone with ranges spanning an order of magnitude. Further exploration is needed to determine the dose that balances reversal of respiratory depression with mitigation of withdrawal.

Entities:  

Keywords:  Naloxone; Opioid overdose; Opioid withdrawal

Mesh:

Substances:

Year:  2016        PMID: 27271032      PMCID: PMC4996792          DOI: 10.1007/s13181-016-0559-3

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN: 1556-9039


  10 in total

Review 1.  Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.

Authors:  Terry L Vanden Hoek; Laurie J Morrison; Michael Shuster; Michael Donnino; Elizabeth Sinz; Eric J Lavonas; Farida M Jeejeebhoy; Andrea Gabrielli
Journal:  Circulation       Date:  2010-11-02       Impact factor: 29.690

2.  Drug-poisoning deaths involving heroin: United States, 2000-2013.

Authors:  Holly Hedegaard; Li-Hui Chen; Margaret Warner
Journal:  NCHS Data Brief       Date:  2015-03

3.  Pulmonary edema following naloxone administration in a healthy orthopedic patient.

Authors:  C Johnson; P Mayer; D Grosz
Journal:  J Clin Anesth       Date:  1995-06       Impact factor: 9.452

4.  Profound increase in epinephrine concentration in plasma and cardiovascular stimulation after mu-opioid receptor blockade in opioid-addicted patients during barbiturate-induced anesthesia for acute detoxification.

Authors:  P Kienbaum; N Thürauf; M C Michel; N Scherbaum; M Gastpar; J Peters
Journal:  Anesthesiology       Date:  1998-05       Impact factor: 7.892

5.  Increases in Drug and Opioid Overdose Deaths--United States, 2000-2014.

Authors:  Rose A Rudd; Noah Aleshire; Jon E Zibbell; R Matthew Gladden
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-01-01       Impact factor: 17.586

6.  Naloxone use in a tiered-response emergency medical services system.

Authors:  Daniel Belz; Jacob Lieb; Tom Rea; Mickey S Eisenberg
Journal:  Prehosp Emerg Care       Date:  2006 Oct-Dec       Impact factor: 3.077

7.  Cardiovascular effects of fentanyl reversal by naloxone at varying arterial carbon dioxide tensions in dogs.

Authors:  C A Mills; J W Flacke; J D Miller; L J Davis; B C Bloor; W E Flacke
Journal:  Anesth Analg       Date:  1988-08       Impact factor: 5.108

8.  Adverse events after naloxone treatment of episodes of suspected acute opioid overdose.

Authors:  Ingebjørg Buajordet; Anne-Cathrine Naess; Dag Jacobsen; Odd Brørs
Journal:  Eur J Emerg Med       Date:  2004-02       Impact factor: 2.799

9.  Increases in heroin overdose deaths - 28 States, 2010 to 2012.

Authors:  Rose A Rudd; Len J Paulozzi; Michael J Bauer; Richard W Burleson; Rick E Carlson; Dan Dao; James W Davis; Jennifer Dudek; Beth Ann Eichler; Jessie C Fernandes; Anna Fondario; Barbara Gabella; Beth Hume; Theron Huntamer; Mbabazi Kariisa; Thomas W Largo; JoAnne Miles; Ashley Newmyer; Daniela Nitcheva; Beatriz E Perez; Scott K Proescholdbell; Jennifer C Sabel; Jessica Skiba; Svetla Slavova; Kathy Stone; John M Tharp; Tracy Wendling; Dagan Wright; Anne M Zehner
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-10-03       Impact factor: 17.586

10.  The empiric use of naloxone in patients with altered mental status: a reappraisal.

Authors:  J R Hoffman; D L Schriger; J S Luo
Journal:  Ann Emerg Med       Date:  1991-03       Impact factor: 5.721

  10 in total
  6 in total

Review 1.  Naloxone dosage for opioid reversal: current evidence and clinical implications.

Authors:  Rachael Rzasa Lynn; J L Galinkin
Journal:  Ther Adv Drug Saf       Date:  2017-12-13

2.  In Response to: "The Evolution of Recommended Naloxone Dosing for Opioid Overdose by Medical Specialty".

Authors:  Juliana Lombardi; Eric Villeneuve; Sophie Gosselin
Journal:  J Med Toxicol       Date:  2016-10-24

3.  Ondansetron Does Not Reduce Withdrawal in Patients With Physical Dependence on Chronic Opioid Therapy.

Authors:  Larry F Chu; John Sun; Anna Clemenson; Matthew J Erlendson; Tom Rico; Erika Cornell; Hannah Obasi; Zahra N Sayyid; Ellen M Encisco; Jeff Yu; Jamison G Gamble; Ian Carroll; J David Clark
Journal:  J Addict Med       Date:  2017 Sep/Oct       Impact factor: 3.702

4.  Naloxone interventions in opioid overdoses: a systematic review protocol.

Authors:  Lindsay Victoria Shaw; Jessica Moe; Roy Purssell; Jane A Buxton; Jesse Godwin; Mary M Doyle-Waters; Penelope M A Brasher; Jeffrey P Hau; Jason Curran; Corinne M Hohl
Journal:  Syst Rev       Date:  2019-06-11

5.  A Fatal Case of Opioid Intoxication After Raw Poppy Plant Ingestion.

Authors:  Gurkan Bozan; Hasan Bora Ulukapi; Ummuhan Oncul; Serkan Levent; Ener C Dinleyici
Journal:  Cureus       Date:  2021-02-06

6.  Adverse events related to bystander naloxone administration in cases of suspected opioid overdose in British Columbia: An observational study.

Authors:  Amina Moustaqim-Barrette; Kristi Papamihali; Sierra Williams; Max Ferguson; Jessica Moe; Roy Purssell; Jane A Buxton
Journal:  PLoS One       Date:  2021-10-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.